

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunoGenesis Doses First Patient in IMGS-101 Combo Trial for Solid Tumors
Details : IMGS-101 (evofosfamide) is a DNA inhibitor, which is being evaluated for the treatment of rmetastatic castration-resistant prostate cancer, pancreatic, & HPV(-) head & neck tumors.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunoGenesis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunoGenesis
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Agenus
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Agenus
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 31, 2017
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable
SARC021C: A Continuation Study of TH-CR-406/SARC021
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 18, 2016
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Molecular Templates | Zuyderland Medical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Esophageal Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 06, 2015
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Molecular Templates | Zuyderland Medical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 05, 2015
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Molecular Templates | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 30, 2015
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Molecular Templates | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 02, 2014
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Molecular Templates
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 21, 2014
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
